IMBCR is dedicated to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care.
Enzalutamide Improves Undetectable PSA Levels in Nonmetastatic CSPC
Apalutamide/ADT Confers 100% Recurrence-Free Survival in High-Risk Prostate Cancer
TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer
UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset